Matthias P Ebert Selected Research

Leukopenia

11/2022

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthias P Ebert Research Topics

Disease

32	Neoplasms (Cancer) 11/2022 - 11/2003
14	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 01/2015
8	Stomach Neoplasms (Stomach Cancer) 10/2021 - 12/2010
5	Adenocarcinoma 11/2022 - 12/2012
4	Fibrosis (Cirrhosis) 12/2022 - 01/2016
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 05/2008
3	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2015
3	Liver Diseases (Liver Disease) 12/2022 - 01/2016
3	Infections 08/2022 - 07/2002
3	Carcinoma (Carcinomatosis) 06/2020 - 03/2008
3	Inflammation (Inflammations) 01/2020 - 01/2009
2	COVID-19 08/2022 - 10/2020
2	Adenoma (Adenomas) 12/2021 - 01/2020
2	Disease Progression 01/2019 - 10/2007
2	Gastritis 04/2015 - 01/2009
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2022
1	Acute Liver Failure (Fulminant Hepatic Failure) 12/2022
1	Liver Failure 12/2022
1	Pathologic Complete Response 11/2022
1	Leukopenia 11/2022
1	Diarrhea 11/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Rectal Neoplasms (Rectal Cancer) 01/2022
1	Fatigue 10/2021
1	Microsatellite Instability 10/2021
1	Turcot syndrome 10/2021
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Hypersensitivity (Allergy) 01/2020
1	Cancer Pain 01/2020
1	Thrombosis (Thrombus) 04/2019
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 03/2019
1	Carcinogenesis 01/2019
1	Leukemia 01/2019
1	Critical Illness (Critically Ill) 01/2018

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2007
7	Proteins (Proteins, Gene)FDA Link 11/2022 - 03/2008
6	Bevacizumab (Avastin)FDA Link 12/2022 - 01/2016
5	Pharmaceutical PreparationsIBA 12/2022 - 05/2014
4	Trastuzumab (Herceptin)FDA Link 11/2022 - 12/2010
3	ErbB Receptors (EGF Receptor)IBA 11/2022 - 03/2008
3	Histones (Histone)IBA 11/2022 - 07/2012
3	ProteomeIBA 12/2010 - 05/2008
2	Capecitabine (Xeloda)FDA Link 12/2022 - 12/2012
2	Antineoplastic Agents (Antineoplastics)IBA 11/2022 - 01/2022
2	Histone Deacetylase InhibitorsIBA 11/2022 - 07/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 06/2006
2	Growth Differentiation Factor 2IBA 01/2022 - 01/2017
2	Immune Checkpoint InhibitorsIBA 08/2020 - 01/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2019 - 05/2014
2	Messenger RNA (mRNA)IBA 01/2019 - 03/2008
2	PPAR gammaIBA 01/2019 - 03/2008
2	DNA (Deoxyribonucleic Acid)IBA 04/2015 - 01/2015
1	Serum AlbuminIBA 12/2022
1	AlbuminsIBA 12/2022
1	pertuzumabIBA 11/2022
1	Fluorouracil (Carac)FDA LinkGeneric 11/2022
1	Leucovorin (Folinic Acid)FDA Link 11/2022
1	Docetaxel (Taxotere)FDA Link 11/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2022
1	Lysine (L-Lysine)FDA Link 11/2022
1	MethyltransferasesIBA 11/2022
1	Biological ProductsIBA 01/2022
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2022
1	atezolizumabIBA 01/2022
1	myotubularinIBA 12/2021
1	Hemoglobins (Hemoglobin)IBA 10/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2021
1	sepantroniumIBA 01/2021
1	Rituximab (Mabthera)FDA Link 10/2020
1	Chemokine ReceptorsIBA 01/2020
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2020
1	ChemokinesIBA 01/2020
1	Angiogenesis InhibitorsIBA 01/2020
1	CCR7 ReceptorsIBA 01/2020
1	AntibodiesIBA 01/2020
1	N 30IBA 01/2020
1	Neutralizing AntibodiesIBA 01/2020
1	Aryl Hydrocarbon Receptor Nuclear TranslocatorIBA 07/2019
1	IpilimumabIBA 03/2019
1	NivolumabIBA 03/2019
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	Cell-Free Nucleic AcidsIBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2019
1	CytokinesIBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Gemcitabine FDA Link 07/2018
1	130-nm albumin-bound paclitaxelIBA 07/2018

Therapy/Procedure

20	Therapeutics 11/2022 - 07/2002
5	Drug Therapy (Chemotherapy) 11/2022 - 07/2012
4	Immunotherapy 01/2022 - 01/2019
3	Combination Drug Therapy (Combination Chemotherapy) 07/2018 - 07/2012
1	Artificial Respiration (Mechanical Ventilation) 08/2022
1	Molecular Targeted Therapy 01/2022
1	Chemoradiotherapy 01/2022
1	Neoadjuvant Therapy 01/2022
1	Precision Medicine 01/2022
1	Aftercare (After-Treatment) 01/2022
1	Polypharmacy 06/2020
1	Operative Surgical Procedures 06/2020
1	Injections 01/2020